Doripenem: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 26: Line 26:
'''| [[Doripenem labels and packages|Labels and Packages]]'''
'''| [[Doripenem labels and packages|Labels and Packages]]'''


==Mechanisms of Action==
==Mechanism of Action==


==References==
==References==

Revision as of 01:48, 26 December 2013

Doripenem
DORIBAX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup carbapenem. It was launched byShionogi Co. of Japan under the brand name "Finibax" in 2005. It is particularly active against Pseudomonas aeruginosa.

Category

Carbapenem

US Brand Names

Doribax®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages

Mechanism of Action

References